BRPI1007624A2 - composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste - Google Patents

composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste

Info

Publication number
BRPI1007624A2
BRPI1007624A2 BRPI1007624A BRPI1007624A BRPI1007624A2 BR PI1007624 A2 BRPI1007624 A2 BR PI1007624A2 BR PI1007624 A BRPI1007624 A BR PI1007624A BR PI1007624 A BRPI1007624 A BR PI1007624A BR PI1007624 A2 BRPI1007624 A2 BR PI1007624A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
salt
preparing
Prior art date
Application number
BRPI1007624A
Other languages
English (en)
Inventor
Gilbert M Rishton
Susan Catalano
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of BRPI1007624A2 publication Critical patent/BRPI1007624A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1007624A 2009-04-09 2010-04-06 composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste BRPI1007624A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16798409P 2009-04-09 2009-04-09
US30866710P 2010-02-26 2010-02-26
US30909110P 2010-03-01 2010-03-01
PCT/US2010/030130 WO2010118055A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Publications (1)

Publication Number Publication Date
BRPI1007624A2 true BRPI1007624A2 (pt) 2016-07-26

Family

ID=42936539

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007624A BRPI1007624A2 (pt) 2009-04-09 2010-04-06 composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste

Country Status (12)

Country Link
US (3) US8765816B2 (pt)
EP (1) EP2416795B1 (pt)
JP (1) JP2012523418A (pt)
CN (2) CN105968022A (pt)
AU (2) AU2010234518A1 (pt)
BR (1) BRPI1007624A2 (pt)
DK (1) DK2416795T3 (pt)
ES (1) ES2545795T3 (pt)
IL (1) IL215645A0 (pt)
RU (1) RU2595720C2 (pt)
SG (2) SG176772A1 (pt)
WO (1) WO2010118055A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105968022A (zh) 2009-04-09 2016-09-28 考格尼申治疗股份有限公司 认知衰退的抑制剂
BR112012002246A2 (pt) 2009-07-31 2019-09-24 Cognition Therapeutics Inc composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
CA2846604A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
AU2012298617B2 (en) * 2011-08-25 2016-07-14 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
NZ629855A (en) 2012-03-20 2016-01-29 Adamed Sp Zoo Sulphonamide derivatives of benzylamine for the treatment of cns diseases
AU2014342520B2 (en) 2013-10-28 2019-08-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
IL270251B2 (en) 2017-05-15 2025-01-01 Cognition Therapeutics Inc 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
JP2023526515A (ja) 2020-05-20 2023-06-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ リソソーム蓄積症をヒスタチンペプチドで処置するための方法
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321386A (en) * 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
JPS62283922A (ja) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
JPH01180822A (ja) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DK0724561T3 (da) * 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
CN1093079A (zh) * 1993-03-30 1994-10-05 陈英俊 由具有愈创木酚结构之香辛类化合物及其去氢化合物衍生之肾上腺素激性乙型阻断剂
CN1147459C (zh) * 1994-10-21 2004-04-28 Nps药物有限公司 钙受体活性化合物
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
AU6497200A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
WO2003016274A2 (en) * 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
JP2004002517A (ja) * 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
WO2004110387A2 (en) 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
AU2005253776B8 (en) 2004-06-21 2012-02-02 King's College London Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2008512417A (ja) 2004-09-10 2008-04-24 ユセベ ファルマ ソシエテ アノニム シグマ受容体リガンド
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
ATE458754T1 (de) 2005-03-05 2010-03-15 Abbott Gmbh & Co Kg Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper
WO2006138349A1 (en) 2005-06-15 2006-12-28 Kim Darrick S H L Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
MX2008011754A (es) 2006-03-17 2008-09-30 Herbalscience Singapore Pte Ltd Extractos y metodos que comprenden especies de curcuma.
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
WO2008042755A2 (en) * 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
CN101808647A (zh) 2007-05-15 2010-08-18 海利空医疗公司 通过抑制Gpr12治疗认知障碍的方法
US8304547B2 (en) * 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009059214A1 (en) 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
WO2010062260A1 (en) 2008-11-29 2010-06-03 The Thailand Research Fund Virus and target cell interaction inhibition
CN105968022A (zh) 2009-04-09 2016-09-28 考格尼申治疗股份有限公司 认知衰退的抑制剂
BR112012002246A2 (pt) 2009-07-31 2019-09-24 Cognition Therapeutics Inc composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
CA2846604A1 (en) 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease

Also Published As

Publication number Publication date
RU2011145321A (ru) 2013-05-20
US20140371324A1 (en) 2014-12-18
US8765816B2 (en) 2014-07-01
EP2416795A1 (en) 2012-02-15
CN102458435A (zh) 2012-05-16
RU2595720C2 (ru) 2016-08-27
AU2015242954B2 (en) 2016-08-25
ES2545795T3 (es) 2015-09-15
AU2015242954A1 (en) 2015-10-29
US9365491B2 (en) 2016-06-14
DK2416795T3 (en) 2015-08-31
CN105968022A (zh) 2016-09-28
JP2012523418A (ja) 2012-10-04
SG10201404913QA (en) 2014-11-27
US20120095105A1 (en) 2012-04-19
US20160355458A1 (en) 2016-12-08
AU2010234518A1 (en) 2012-02-02
WO2010118055A1 (en) 2010-10-14
EP2416795A4 (en) 2013-12-25
IL215645A0 (en) 2012-01-31
EP2416795B1 (en) 2015-06-03
HK1167323A1 (en) 2013-01-04
SG176772A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
BRPI1007624A2 (pt) composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BR112012003578A2 (pt) composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal.
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112012015248A2 (pt) composto composição farmacêutica,método para inibir ativi dades de ck1, método para inibir atividade de ck2 e uso de um composto ou uma composição farmacêutica
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1012979A2 (pt) composição para cuidado oral, método para preparar a mesma, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]